Our vision is to create a royalty pharma company by generating substantial royalties and milestone payments from ‘out licensing’ the rights to our drugs to large pharma over time.  In addition, our aim is being the leader in the journey of longevity through the provision of our cutting-edge AI enabled ageing clocks through the provision of a B2B2C SaaS platform.
 
Our aims are to drive robust value enhancing growth through:
 

• The generation of royalties and milestones from existing and new "out licensing" agreements; and
• The commercialisation of our leading scientifically backed AI enabled ageing clocks and preventative health solutions.

 
Our strategy is focussed on Greater China, the US, the UK and Europe because of its strong growth profile and because it is where the Group has long experience, deep knowledge and strong relationships.